MELBOURNE, Australia,
Dec. 5, 2012 /PRNewswire/ --
Bluechiip Limited [ASX: BCT] today announced that USA-based high-technology manufacturing
company MiTeGen, LLC has signed a license agreement for tracking of
cryopins.
The Joint Development, Collaboration and License Agreement
with Bluechiip allows MiTeGen to integrate Bluechiip's tracking
technology into the cryopins it manufactures and sells to the likes
of the Australian Synchrotron, for which Bluechiip has just
completed a project, as well as other synchrotrons around the
world. The agreement allows MiTeGen to develop with Bluechiip, and
for MiTeGen to sell this 'enhanced' product.
This adds a further product to Bluechiip's product range and
another revenue stream as the company moves into the
commercialisation phase.
MiTeGen, based in New
York, designs, manufactures and distributes products
for -- among other purposes -- crystallization,
crystallography and x-ray diffraction of proteins, viruses and
small molecule/inorganic compounds. MiTeGen
supplies crystallography goniometer bases -- also commonly
referred to as 'cryopins' -- for crystal mounts which are used
in synchrotrons. MiTeGen's customers include academic, medical,
pharmaceutical, government and industrial laboratories in more than
40 countries.
MiTeGen is one of the world's major suppliers of cryopins,
offering a wider range of cryopin designs than any other
manufacturers, to better meet the varying needs of global
customers. MiTeGen's extensive line of
Goniometer bases include patented reusable bases unique to the
industry and very popular with users. The
cryopin global market is estimated to use 2 million per year in
synchrotrons across the world, with other uses in markets including
research and science which are yet to be explored.
Brett Schwarz, Managing
Director of Bluechiip Limited, said the agreement with MiTeGen
comes on the back of several recent agreements with other major
companies around the globe. "All of these agreements are with
companies that operate in significant markets. These agreements
help validate the bluechiip® technology and underline
how important our technology is when it comes to the accurate
tracking of information on important assets. We are confident that
the agreement with MiTeGen will lead to better products and greater
sales for both organisations, as well as prove the 'platform
technology' nature of the bluechiip® tracking
technology."
Robert Newman, CEO MiTeGen,
said, "MiTeGen has a history of bringing cutting-edge sample
handling innovation to crystallographers. We are
excited to continue this tradition by partnering with Bluechiip to
bring their sample tracking technology to beamlines and
crystallography labs worldwide. The
bluechiip® technology offers numerous advantages over
traditional bar-coding of bases and is extremely well suited for
cryogenic conditions, as well as room temperature
studies."
About Bluechiip Limited:
Bluechiip has developed a wireless tracking solution for
the healthcare and life science, security, defence and
manufacturing industries which represents a generational change
from current methods such as labels (hand-written and pre-printed),
barcodes (linear and 2D) and microelectronic integrated circuit
(IC)-based RFID (Radio Frequency Identification).
The unique tag is based on MEMS technology and contains no
electronics. The tag can either be embedded or manufactured into a
storage product, such as vials or bags. Easy identification, along
with any associated information from the tag such as temperature
can be detected by a reader, which can also sense the temperature
of the tagged items. The traditional
identification technologies have significant limitations. Whereas a
barcode requires a visible tag or line-of-sight optical scan,
bluechiip® technology does not.
Unlike labels, barcodes and RFID, the bluechiip®
technology can sense the temperature of each item a tag is attached
to, or embedded in.
The bluechiip® technology has initial
applications in the healthcare industry particularly those
businesses which require cryogenic storage facilities (biobanks and
biorepositories). bluechiip® offers the only technology
that enables accurate and reliable tracking of products including
stem cells, cord blood, and other biospecimens.
In addition to functioning in extreme temperatures, the
bluechiip® tracking solution can survive autoclaving,
gamma irradiation sterilization, humidification, centrifuging,
cryogenic storage and frosting.
The bluechiip® technology has other healthcare
applications in pathology, clinical trials and forensics. Several
other key markets outside of healthcare include cold-chain
logistics/supply chain, security/defence, industrial/manufacturing
and aerospace/aviation.
www.bluechiip.com
About MiTeGen
Founded in 2004, MiTeGen designs, manufactures and
distributes products for crystallization, crystallography and x-ray
diffraction of proteins, viruses and small molecule/inorganic
compounds, and for manipulation and measurement of small samples in
cell biology, histology, clinical diagnostics, entomology,
archaeology, art restoration and geology. Its customers include
academic, medical, pharmaceutical, government and industrial
laboratories in more than 40 countries.
www.mitegen.com
For more information:
Brett
Schwarz
Managing
Director, Bluechiip Limited
Ph:
+61-419-367-590
brett.schwarz@bluechiip.com
Richard Allen
Oxygen Financial Public Relations
Ph:
+61-3-9915-6341
richard@oxygenpr.com.au
SOURCE Bluechiip Limited
